JP2017525730A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525730A5 JP2017525730A5 JP2017511734A JP2017511734A JP2017525730A5 JP 2017525730 A5 JP2017525730 A5 JP 2017525730A5 JP 2017511734 A JP2017511734 A JP 2017511734A JP 2017511734 A JP2017511734 A JP 2017511734A JP 2017525730 A5 JP2017525730 A5 JP 2017525730A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- pharmaceutical composition
- pharmaceutically acceptable
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 1
- 229960002438 carfilzomib Drugs 0.000 claims 1
- 108010021331 carfilzomib Proteins 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043929P | 2014-08-29 | 2014-08-29 | |
| US62/043,929 | 2014-08-29 | ||
| PCT/US2015/047472 WO2016033486A1 (en) | 2014-08-29 | 2015-08-28 | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525730A JP2017525730A (ja) | 2017-09-07 |
| JP2017525730A5 true JP2017525730A5 (cg-RX-API-DMAC10.html) | 2018-08-09 |
| JP6502479B2 JP6502479B2 (ja) | 2019-04-17 |
Family
ID=54238507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511734A Active JP6502479B2 (ja) | 2014-08-29 | 2015-08-28 | Ｍｃｌ−１タンパク質を阻害する化合物 |
Country Status (41)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2018015526A1 (en) | 2016-07-22 | 2018-01-25 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof |
| JP6453507B2 (ja) * | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| MX2020001719A (es) * | 2017-08-15 | 2020-11-06 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y metodos de uso. |
| US10676485B2 (en) * | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| ES3036998T3 (en) * | 2017-08-18 | 2025-09-26 | Amgen Inc | Compounds that inhibit mcl-1 protein |
| EP3676270A1 (en) * | 2017-08-29 | 2020-07-08 | Amgen Inc. | Macrocyclic compounds that inhibit mcl-1 protein |
| EP3762393B1 (en) | 2018-03-05 | 2023-01-11 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists |
| WO2019222112A1 (en) * | 2018-05-14 | 2019-11-21 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| AU2019374907A1 (en) | 2018-11-09 | 2021-06-03 | Prelude Therapeutics, Incorporated | Spiro-sulfonamide derivatives as inhibitors of Myeloid Cell Leukemia-1 (Mcl-1) protein |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| CN112867722B (zh) * | 2019-01-18 | 2022-09-23 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大螺环醚(macrocyclic spiroethers) |
| WO2020236817A2 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2020254471A1 (en) * | 2019-06-21 | 2020-12-24 | Janssen Pharmaceutica Nv | Macrocyclic inhibitors of mcl-1 |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| ES2987630T3 (es) | 2019-07-09 | 2024-11-15 | Janssen Pharmaceutica Nv | Derivados de espirociclos macrocíclicos como inhibidores de MCL-1 |
| EP3771469A1 (en) * | 2019-07-30 | 2021-02-03 | Amgen, Inc | Formulations and dosages for administering a compound that inhibits mcl1 protein |
| WO2021047616A1 (zh) * | 2019-09-12 | 2021-03-18 | 苏州亚盛药业有限公司 | 氧氮杂环庚烷类螺环化合物、中间体及其制备方法 |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| MY209360A (en) | 2019-10-31 | 2025-07-03 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| IL320513A (en) | 2019-11-04 | 2025-06-01 | Revolution Medicines Inc | RAS inhibitors |
| CR20220240A (es) * | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| JP7441947B2 (ja) * | 2019-11-26 | 2024-03-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ１阻害剤を調製するためのプロセス及び中間体 |
| PL4081305T3 (pl) | 2019-12-24 | 2025-02-10 | Carna Biosciences, Inc. | Związki modulujące kinazę diacyloglicerolową |
| EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| KR20220143906A (ko) * | 2020-02-21 | 2022-10-25 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 거대환식 인돌 유도체 |
| JP2021161114A (ja) * | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| US20230212191A1 (en) * | 2020-04-16 | 2023-07-06 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| CA3181922A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
| EP4146622A1 (en) * | 2020-05-06 | 2023-03-15 | Amgen Inc. | Synthesis of sulfonamide intermediates |
| IL297522A (en) | 2020-05-06 | 2022-12-01 | Amgen Inc | Synthesis of vinylic intermediates |
| BR112022022400A2 (pt) | 2020-05-06 | 2022-12-13 | Amgen Inc | Síntese de intermediários de álcool vinílico protegidos |
| TWI827924B (zh) * | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| TWI867217B (zh) * | 2020-05-06 | 2024-12-21 | 美商安進公司 | 乙烯基環丁基中間體之合成 |
| EP4165050A1 (en) | 2020-06-10 | 2023-04-19 | JANSSEN Pharmaceutica NV | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| MX2023002691A (es) * | 2020-09-03 | 2023-05-03 | Amgen Inc | Desimetrización de diol mediante sustitución aromática nucleófila. |
| US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
| CN120590359A (zh) * | 2020-11-19 | 2025-09-05 | 吉利德科学公司 | 用于制备大环mcl1抑制剂的方法和中间体 |
| KR20230138444A (ko) | 2020-11-24 | 2023-10-05 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| EP4251604A1 (en) * | 2020-11-25 | 2023-10-04 | Amgen Inc. | Enantioselective alkenylation of aldehydes |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| WO2022122667A1 (en) | 2020-12-07 | 2022-06-16 | Cellestia Biotech Ag | Pharmaceutical combinations for treating cancer |
| KR20230121806A (ko) | 2020-12-17 | 2023-08-21 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 마크로사이클릭 분지형 3-플루오로-부트-3-엔아미드 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CN117295749A (zh) | 2021-04-26 | 2023-12-26 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环2-烯丙基四氢呋喃 |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| KR20240019330A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항체 약물 접합체의 조합 |
| CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TWI857377B (zh) | 2021-10-28 | 2024-10-01 | 美商基利科學股份有限公司 | 嗒-3(2h)-酮衍生物 |
| MX2024005066A (es) | 2021-10-29 | 2024-05-24 | Gilead Sciences Inc | Compuestos de cd73. |
| US20250051359A1 (en) | 2021-11-16 | 2025-02-13 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| PE20242225A1 (es) | 2022-03-17 | 2024-11-19 | Gilead Sciences Inc | Degradadores de dedos de zinc de la familia ikaros y usos de estos |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| JP2025513774A (ja) | 2022-04-05 | 2025-04-30 | アムジエン・インコーポレーテツド | Ｍｃｌ－１アンタゴニストの塩形態及び溶媒和物 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| JP2025511331A (ja) * | 2022-04-05 | 2025-04-15 | アムジエン・インコーポレーテツド | Ｍｃｉ－１アンタゴニストの非晶質及び結晶性形態 |
| AU2023256670A1 (en) | 2022-04-21 | 2024-10-17 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| JP2025517435A (ja) | 2022-05-20 | 2025-06-05 | ノバルティス アーゲー | 抗新生物薬化合物の抗体－薬物コンジュゲートおよびその使用の方法 |
| CA3260083A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | CD73 COMPOUNDS |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| KR20250122479A (ko) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
| TW202540185A (zh) | 2023-11-22 | 2025-10-16 | 法商施維雅藥廠 | 抗cd74抗體藥物結合物及其使用方法 |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| WO2007008627A2 (en) * | 2005-07-07 | 2007-01-18 | Abbott Laboratories | Apoptosis promoters |
| EP3243814B1 (en) * | 2007-04-16 | 2018-10-17 | AbbVie Inc. | 7-substituted indole as mcl-1 inhibitors |
| JP5536647B2 (ja) * | 2007-07-27 | 2014-07-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピロロピリミジン |
| US8975286B2 (en) * | 2009-08-20 | 2015-03-10 | Merck Sharp & Dohme Corp. | Ether benzotriazole derivatives |
| IN2012DN02816A (cg-RX-API-DMAC10.html) * | 2009-10-08 | 2015-07-24 | Sanford Burnham Med Res Inst | |
| CA2787784A1 (en) | 2010-01-29 | 2011-08-04 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| WO2013052943A2 (en) | 2011-10-06 | 2013-04-11 | The Regents Of The University Of Michgian | Small molecule inhibitors of mcl-1 and uses thereof |
| EP2831067B1 (en) | 2012-03-29 | 2017-11-01 | The Regents Of The University Of Michigan | Small molecule inhibitors of mcl-1 and uses thereof |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
-
2015
- 2015-08-27 JO JOP/2015/0208A patent/JO3474B1/ar active
- 2015-08-28 MA MA40111A patent/MA40111B1/fr unknown
- 2015-08-28 TW TW104128490A patent/TWI676628B/zh active
- 2015-08-28 ES ES15772048T patent/ES2706309T3/es active Active
- 2015-08-28 KR KR1020177008470A patent/KR102466351B1/ko active Active
- 2015-08-28 PT PT15772048T patent/PT3186259T/pt unknown
- 2015-08-28 LT LTEP15772048.3T patent/LT3186259T/lt unknown
- 2015-08-28 TN TN2017000067A patent/TN2017000067A1/en unknown
- 2015-08-28 EP EP18187957.8A patent/EP3424931B1/en active Active
- 2015-08-28 HR HRP20190053TT patent/HRP20190053T1/hr unknown
- 2015-08-28 UA UAA201702910A patent/UA118233C2/uk unknown
- 2015-08-28 JP JP2017511734A patent/JP6502479B2/ja active Active
- 2015-08-28 TR TR2019/01312T patent/TR201901312T4/tr unknown
- 2015-08-28 EA EA201790492A patent/EA031223B1/ru not_active IP Right Cessation
- 2015-08-28 ME MEP-2019-12A patent/ME03313B/me unknown
- 2015-08-28 PL PL15772048T patent/PL3186259T3/pl unknown
- 2015-08-28 SI SI201530586T patent/SI3186259T1/sl unknown
- 2015-08-28 SM SM20190048T patent/SMT201900048T1/it unknown
- 2015-08-28 AU AU2015308735A patent/AU2015308735B2/en active Active
- 2015-08-28 BR BR112017004209-6A patent/BR112017004209B1/pt active IP Right Grant
- 2015-08-28 ES ES18187957T patent/ES2777478T3/es active Active
- 2015-08-28 SG SG11201701525WA patent/SG11201701525WA/en unknown
- 2015-08-28 CR CR20170116A patent/CR20170116A/es unknown
- 2015-08-28 PE PE2017000362A patent/PE20170892A1/es unknown
- 2015-08-28 HU HUE15772048A patent/HUE041806T2/hu unknown
- 2015-08-28 CN CN201580054328.4A patent/CN107001387B/zh active Active
- 2015-08-28 MX MX2017002656A patent/MX379155B/es unknown
- 2015-08-28 EP EP15772048.3A patent/EP3186259B1/en active Active
- 2015-08-28 MY MYPI2017000299A patent/MY176235A/en unknown
- 2015-08-28 RS RS20190094A patent/RS58276B1/sr unknown
- 2015-08-28 US US14/839,149 patent/US9562061B2/en active Active
- 2015-08-28 DK DK15772048.3T patent/DK3186259T3/en active
- 2015-08-28 WO PCT/US2015/047472 patent/WO2016033486A1/en not_active Ceased
- 2015-08-28 CA CA2959615A patent/CA2959615C/en active Active
- 2015-08-28 AP AP2017009827A patent/AP2017009827A0/en unknown
- 2015-08-31 AR ARP150102791A patent/AR101729A1/es active IP Right Grant
- 2015-08-31 UY UY0001036285A patent/UY36285A/es active IP Right Grant
-
2016
- 2016-12-12 US US15/376,456 patent/US10100063B2/en active Active
-
2017
- 2017-02-27 CL CL2017000469A patent/CL2017000469A1/es unknown
- 2017-02-28 PH PH12017500367A patent/PH12017500367A1/en unknown
- 2017-02-28 IL IL250843A patent/IL250843B/en active IP Right Grant
- 2017-03-10 ZA ZA2017/01763A patent/ZA201701763B/en unknown
- 2017-03-28 CO CONC2017/0002998A patent/CO2017002998A2/es unknown
-
2018
- 2018-03-07 IL IL257942A patent/IL257942B/en active IP Right Grant
- 2018-05-02 ZA ZA2018/02865A patent/ZA201802865B/en unknown
- 2018-09-05 US US16/121,750 patent/US10836779B2/en active Active
- 2018-09-06 US US16/123,030 patent/US10494381B2/en active Active
-
2019
- 2019-01-28 CY CY20191100117T patent/CY1121195T1/el unknown
- 2019-09-13 US US16/569,927 patent/US11001598B2/en active Active
-
2020
- 2020-10-21 US US17/075,864 patent/US11685747B2/en active Active
-
2023
- 2023-05-08 US US18/313,703 patent/US12024529B2/en active Active